Non-pharmacological Interventions on Pain and Quality of Life in Chemotherapy Induced Polyneuropathy: Systematic Review and Meta-Analysis.
Papadopoulou M, Stamou M, Bakalidou D, Moschovos C, Zouvelou V, Zis P, Tzartos J, Chroni E, Michopoulos I, Tsivgoulis G.
In Vivo. 2023 Jan-Feb;37(1):47-56. doi: 10.21873/invivo.13053.
Small-fibre polyneuropathy caused by chemical agent resistant coating.
Marshall B, Sharma Md U, Tsakadze Md N, Rossi Md FH.
BMJ Case Rep. 2021 Jun 1;14(6):e242438. doi: 10.1136/bcr-2021-242438.
Fluoroquinolone-Induced Demyelinating Polyneuropathy.
Al-Chalabi M, Martinez Salazar A, Bradshaw A.
J Clin Neuromuscul Dis. 2024 Sep 1;26(1):49-53. doi: 10.1097/CND.0000000000000496.
Toxic Neuropathies.
Karam C, Dyck PJ.
Semin Neurol. 2015 Aug;35(4):448-57. doi: 10.1055/s-0035-1558977. Epub 2015 Oct 6.
Atorvastatin-induced polyneuropathy.
Silverberg C.
Ann Intern Med. 2003 Nov 4;139(9):792-3. doi: 10.7326/0003-4819-139-9-200311040-00022.
Organophosphate-induced delayed polyneuropathy.
Lotti M, Moretto A.
Toxicol Rev. 2005;24(1):37-49. doi: 10.2165/00139709-200524010-00003.
Axonal sensorimotor polyneuropathy after starting guselkumab.
Hamadah I, Chisti MA.
J Dermatolog Treat. 2022 Jun;33(4):2371-2372. doi: 10.1080/09546634.2021.1914304. Epub 2021 Aug 1.
Causes of polyneuropathy.
Freemon FR.
Acta Neurol Scand Suppl. 1975;59:3-43.
Polyneuropathy by statins: case report.
Ruiz Anzola YS, Simões L, Borges S.
Med Clin (Barc). 2018 Nov 9;151(9):378-379. doi: 10.1016/j.medcli.2017.11.043. Epub 2017 Dec 30.
Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.
Zedan AH, Vilholm OJ.
Basic Clin Pharmacol Toxicol. 2014 Aug;115(2):193-200. doi: 10.1111/bcpt.12262. Epub 2014 May 24.
